跳至主要内容
临床试验/NCT06558539
NCT06558539尚未招募3 期

Study on the Efficacy of Wearable Transcutaneous Tibial Nerve Stimulation for Persistent Overactive Bladder Symptoms Post Benign Prostatic Hyperplasia Surgery

Qing Yuan0 个研究点目标入组 90 人开始时间: 2024年9月1日最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
90
主要终点
Average Daily Urination Frequency Compared to Baseline

研究概览

简要总结

A single-center, randomized, parallel-controlled design. Approximately 90 cases of persistent overactive bladder symptoms post benign prostatic hyperplasia surgery are expected to be enrolled. The study participants will be randomly assigned to three groups, with 30 participants in each group.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
50 Years 至 80 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • 1. Patients with overactive bladder before benign prostatic hyperplasia 2.Overactive bladder still exists 1 month after the operation of benign prostatic hyperplasia; 3.50 ≤ age ≤80 , male 4.72-hour urination diary showed an average of ≥8 urination times every 24 hours at baseline

排除标准

  • 未提供

结局指标

主要结局

Average Daily Urination Frequency Compared to Baseline

时间窗: treatment during 12 weeks : assessments at weeks 4, 8, and 12.

At the end of Weeks 4, 8, and 12, the change in average daily urination frequency compared to baseline will be calculated using the participants' 72-hour voiding diaries

次要结局

  • Average Daily Nocturia Frequency Compared to Baseline(treatment during 12 weeks : assessments at weeks 4, 8, and 12.)
  • Average Voided Volume per Urination Compared to Baseline(treatment during 12 weeks : assessments at weeks 4, 8, and 12.)
  • Average Urinary Urgency Score(treatment during 12 weeks : assessments at weeks 4, 8, and 12.)
  • SAS Compared to Baseline(treatment during 12 weeks : assessments at weeks 4, 8, and 12.)
  • Potential Adverse Events Related by TTNS(Entire Study)
  • Average Daily Incontinence Episodes(treatment during 12 weeks : assessments at weeks 4, 8, and 12.)
  • AUA-SI-QOL Compared to Baseline(treatment during 12 weeks : assessments at weeks 4, 8, and 12.)
  • OABSS Compared to Baseline(treatment during 12 weeks : assessments at weeks 4, 8, and 12.)
  • PPBC-S Compared to Baseline(treatment during 12 weeks : assessments at weeks 4, 8, and 12.)
  • Participant Satisfaction(treatment during 12 weeks : assessments at weeks 4, 8, and 12.)

研究者

发起方
Qing Yuan
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Qing Yuan

Associate Chief Physician of Urology

Chinese PLA General Hospital

相似试验